Loading patent…
AssigneePfizer Inc.
InventorsDavid A. Fryburg, Janice C. Parker
Estimating the term…
The present invention provides methods of treating non-insulin dependent diabetes mellitus, insulin resistance, Syndrome X, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, polycystic ovary syndrome, cataracts, hyperglycemia, or impaired glucose tolerance, the methods comprising the step of administering to a patient having or at risk of having non-insulin dependent diabetes mellitus, insulin resistance, Syndrome X, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, polycystic ovary syndrome, cataracts, hyperglycemia, or impaired glucose tolerance a synergistic amount of: 1) a sulfonylurea, a non-sulfonylurea K+ ATP channel blocker, or a sulfonylurea and a non-sulfonylurea K+ ATP channel blocker; and 2) a cAMP phosphodiesterase type 3 inhibitor. The present invention also provides kits and pharmaceutical compositions that comprise: 1) a sulfonylurea, a non-sulfonylurea K+ ATP channel blocker, or a sulfonylurea and a non-sulfonylurea K+ ATP channel blocker; and 2) a cAMP phosphodiesterase type 3 inhibitor. The present invention also relates to kits and pharmaceutical compositions that comprise 1) a sulfonylurea, a non-sulfonylurea K+ ATP channel blocker, or a sulfonylurea and a non-sulfonylurea K+ ATP channel blocker; 2) a cAMP phosphodiesterase type 3 inhibitor; and 3) an additional compound useful for the treatment of non-insulin dependent diabetes mellitus, insulin resistance, Syndrome X, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, polycystic ovary syndrome, cataracts, hyperglycemia, or impaired glucose tolerance.
A method of treating non-insulin dependent diabetes mellitus, the method comprising the step of administering to a patient having or at risk of having non-insulin dependent diabetes a synergistic amount of:
A method of treating insulin resistance, the method comprising the step of administering to a patient having or at risk of having insulin resistance a synergistic amount of:
A method of treating Syndrome X, the method comprising the step of administering to a patient having or at risk of having Syndrome X a synergistic amount of:
A method of treating diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, polycystic ovary syndrome, or cataracts, the method comprising the step of administering to a patient having or at risk of having diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, polycystic ovary syndrome, or cataracts a synergistic amount of:
A method of treating hyperglycemia, the method comprising the step of administering to a patient having or at risk of having hyperglycemia a synergistic amount of:
A method of treating impaired glucose tolerance, the method comprising the step of administering to a patient having or at risk of having impaired glucose tolerance a synergistic amount of:
A pharmaceutical composition comprising a sulfonylurea or non-sulfonylurea K+ ATP channel blocker and a cAMP phosphodiesterase type 3 inhibitor.
A pharmaceutical composition comprising a sulfonylurea, a non-sulfonylurea K+ ATP channel blocker, and a cAMP phosphodiesterase type 3 inhibitor.
A kit for the treatment of non-insulin dependent diabetes mellitus, the kit comprising:
A kit for the treatment of non-insulin dependent diabetes mellitus, insulin resistance, Syndrome X, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, polycystic ovary syndrome, cataracts, hyperglycemia, or impaired glucose tolerance, the kit comprising:
A kit for the treatment of non-insulin dependent diabetes mellitus, insulin resistance, Syndrome X, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, polycystic ovary syndrome, cataracts, hyperglycemia, or impaired glucose tolerance, the kit comprising:
Dependencies are inferred from the claim text.